Last update 25 Jun 2025

212Pb-DOTAM-GRPR1

Overview

Basic Info

Drug Type
Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals
Synonyms
212PB-GRPR
Target
GRPR
Action
antagonists
Mechanism
GRPR antagonists(Gastrin releasing peptide receptor antagonists), Ionising radiation emitters
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [2]
Active Indication
Breast CancerColonic CancerGRPR-positive tumors+ [4]
Inactive Indication-
Originator Organization
Orano Med LLCOrano Med LLC
Active Organization
Orano Med LLCOrano Med LLC
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with 212Pb-DOTAM-GRPR1
NCT05283330
/ RecruitingPhase 1
A Phase 1 Open-Label Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
100 Clinical Results associated with 212Pb-DOTAM-GRPR1
Login to view more data
100 Translational Medicine associated with 212Pb-DOTAM-GRPR1
Login to view more data
100 Patents (Medical) associated with 212Pb-DOTAM-GRPR1
Login to view more data
100 Deals associated with 212Pb-DOTAM-GRPR1
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Colonic CancerPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
GRPR-positive tumorsPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Melanoma, Cutaneous MalignantPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Metastatic castration-resistant prostate cancerPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Non-Small Cell Lung CancerPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Uterine Cervical CancerPhase 1
United States
Orano Med LLCOrano Med LLC
22 Dec 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free